Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of HRS-4729 Injection in Participants With Type 2 Diabetes

NCT07843862 is registered in ClinicalTrials.gov with Fujian Shengdi Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07843862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07843862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of HRS-4729 Injection in Participants With Type 2 Diabetes
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
July 31, 2027
Enrollment
240 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes